How Prosion Therapeutics uses CDD Vault to pioneer ProM drug discovery

Prosion Therapeutics is pioneering a new class of small-molecule drugs that make previously “undruggable” protein–protein interactions actionable. Using the CDD Vault platform as its unified ELN and data hub, the team has accelerated ProM discovery, streamlined collaboration across Cologne and Berlin, and advanced a first-in-class inhibitor with demonstrated proof-of-concept in metastatic cancer models.